Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A M van der Veldt

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Oncology Reports|March 29, 2022
Anti-PD-1: When to Stop TreatmentY Jansen, A A M van der Veldt, G Awada, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 15, 2007
[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]A A M van der Veldt, A J M van den Eertwegh, E Boven
The Netherlands Journal of Medicine|October 24, 2007
Verapamil-induced erythermalgiaP W B Nanayakkara, A A M van der Veldt, S Simsek, et al.
Clinical Endocrinology|September 18, 2007
Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodulesL Hooft, A A M van der Veldt, O S Hoekstra, et al.
British Journal of Cancer|February 11, 2010
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibA A M van der Veldt, M R Meijerink, A J M van den Eertwegh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based studyJ C Janssen, A W Schurink, C Verhoef, et al.
The Journal of Clinical Endocrinology and Metabolism|October 29, 2004
[18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumorL Hooft, A A M van der Veldt, P J van Diest, et al.
ESMO Open|November 15, 2021
Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluationE E A P Mulder, L Smit, D J Grünhagen, et al.
Frontiers in Immunology|February 22, 2021
Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint InhibitionK de Joode, A A M Oostvogels, C H GeurtsvanKessel, et al.
Cancer Treatment Reviews|November 1, 2024
Local administration of immunotherapy for patients with skin cancer: A systematic reviewJ C Janssen, B van Dijk, L L Hoeijmakers, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Oncology Reports|March 29, 2022
Anti-PD-1: When to Stop TreatmentY Jansen, A A M van der Veldt, G Awada, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 15, 2007
[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]A A M van der Veldt, A J M van den Eertwegh, E Boven
The Netherlands Journal of Medicine|October 24, 2007
Verapamil-induced erythermalgiaP W B Nanayakkara, A A M van der Veldt, S Simsek, et al.
Clinical Endocrinology|September 18, 2007
Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodulesL Hooft, A A M van der Veldt, O S Hoekstra, et al.
British Journal of Cancer|February 11, 2010
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibA A M van der Veldt, M R Meijerink, A J M van den Eertwegh, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based studyJ C Janssen, A W Schurink, C Verhoef, et al.
The Journal of Clinical Endocrinology and Metabolism|October 29, 2004
[18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumorL Hooft, A A M van der Veldt, P J van Diest, et al.
ESMO Open|November 15, 2021
Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluationE E A P Mulder, L Smit, D J Grünhagen, et al.
Frontiers in Immunology|February 22, 2021
Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint InhibitionK de Joode, A A M Oostvogels, C H GeurtsvanKessel, et al.
Cancer Treatment Reviews|November 1, 2024
Local administration of immunotherapy for patients with skin cancer: A systematic reviewJ C Janssen, B van Dijk, L L Hoeijmakers, et al.
Pageof 3